Logo for Summit Therapeutics Inc

Summit Therapeutics Investor Relations Material

Latest events

Logo for Summit Therapeutics Inc

Q3 2024

Summit Therapeutics
Logo for Summit Therapeutics

Q3 2024

30 Oct, 2024
Logo for Summit Therapeutics

Study Update

9 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Summit Therapeutics Inc

Access all reports
Summit Therapeutics Inc., headquartered in Menlo Park, California, is a biopharmaceutical company engaged in the research and development of oncology therapies in the United States and the United Kingdom. Its lead pipeline product, ivonescimab, is a novel, bispecific antibody targeting both PD-1 and VEGF. Summit Therapeutics has also initiated two clinical trials with ivonescimab. Additionally, the company's product pipeline includes SMT-738, a novel class of precision antibiotics aimed at treating multidrug-resistant infections, including carbapenem-resistant Enterobacteriaceae infections. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.